Urology news for Wednesday, October 7, 2026

Top 5 in urology

STAMPEDE analysis finds no significant cardiovascular risk increase with ARPI intensification Retrospective · Eur Urol · 2026-10-07
A post hoc analysis of STAMPEDE in 6292 men found 5-year cardiovascular event rates with ARPI intensification (9% in nonmetastatic, 7% in metastatic disease) were comparable to ADT alone, without a statistically significant increase in MACE risk.
Why it matters: Provides reassurance on cardiovascular safety of ARPI treatment intensification in both localized high-risk and metastatic prostate cancer.
AUA Census: fellowship-trained urologists rose from 40% to 46% over a decade, general urology fell Retrospective · Urology · 2026-10-06
Analysis of 2014-2024 AUA Census data shows fellowship-trained urologists increased from 40% to 46% while general urologists decreased from 63% to 54%, with subspecialists concentrated in academic and metropolitan settings.
Why it matters: Highlights a growing access gap as subspecialization trends toward academic, urban practice, with implications for rural and community urology coverage.
Surgical delay of 43+ days to nephroureterectomy linked to worse overall survival in UTUC Retrospective · Clin Genitourin Cancer · 2026-10-07
In 435 patients with upper tract urothelial carcinoma, waiting 43 days or more from diagnosis to radical nephroureterectomy was associated with worse overall survival (HR 1.43) after inverse probability weighting, though cancer-specific and recurrence-free survival differences were not statistically significant.
Why it matters: Adds to evidence that timely surgery after UTUC diagnosis may matter, relevant to scheduling and referral pathways.
Modeled indirect comparison suggests DFS benefit for pembrolizumab-belzutifan vs surveillance in RCC Retrospective · Clin Genitourin Cancer · 2026-10-07
An anchored indirect comparison using KEYNOTE-564 and LITESPARK-022 data estimated a DFS hazard ratio of 0.52 (95% CI 0.39-0.68) for adjuvant pembrolizumab plus belzutifan versus surveillance after nephrectomy for clear cell RCC. This is a modeled, not head-to-head, comparison.
Why it matters: Modeling suggests a possible risk-adapted approach to weigh added toxicity against estimated DFS benefit when considering belzutifan addition post-nephrectomy, pending direct trial confirmation.
Phase 2 trial opens testing PSMA radioligand therapy specifically in Black men with mCRPC Trial opening · ClinicalTrials.gov · 2026-10-06
A phase 2 trial sponsored by Emory University will evaluate the FDA-approved radioligand therapy Pluvicto in African American patients with metastatic castration-resistant prostate cancer, a population underrepresented in prior pivotal trials.
Why it matters: Addresses a known gap in racial representation in PSMA radioligand therapy trial data.

Prostate cancer news

Kairos Pharma reports interim PFS benefit with ENV-105 plus apalutamide in Phase 2 mCRPC trial Phase 1-2 · citybuzz - · 2026-10-06
A company press release reports an interim progression-free survival benefit for investigational ENV-105 (carotuximab) combined with apalutamide in metastatic castration-resistant prostate cancer, based on early interim data from a Phase 2 trial. Details on trial design, arms, and statistical significance were not independently verified.
Why it matters: Interim, company-reported data from a Phase 2 trial should be interpreted cautiously pending peer-reviewed publication or independent confirmation of trial design and significance.
PROpel subgroup analysis: olaparib-abiraterone shows modest rPFS gain without BRCA mutation Retrospective · Eur Urol Oncol · 2026-10-06
In a post hoc subgroup analysis of the Phase 3 PROpel RCT's non-BRCA mutated patients (n=693), olaparib plus abiraterone gave longer median rPFS than placebo plus abiraterone (24.1 vs 19.0 months, HR 0.76, 95% CI 0.61-0.94), but overall survival was not significantly different (39.6 vs 38.0 months, HR 0.91, 95% CI 0.73-1.13).
Why it matters: Clarifies that the rPFS benefit of adding olaparib to abiraterone extends to non-BRCA mCRPC in this post hoc analysis, but survival benefit remains unproven in this subgroup.
Gleason pattern 4 length under 2mm may expand active surveillance eligibility pool Retrospective · BJU Int · 2026-10-06
In a cohort of 2499 radical prostatectomy patients, those with less than 2mm of total Gleason pattern 4 length had adverse pathology and 5-year biochemical recurrence rates similar to favorable intermediate-risk disease, regardless of Grade Group, suggesting this threshold could roughly double the population eligible for active surveillance.
Why it matters: Suggests quantitative Gleason pattern 4 burden could refine active surveillance criteria beyond current risk grouping, pending validation.
Meta-analysis: peritoneal flap reconstruction cuts symptomatic lymphocele after prostatectomy Meta-analysis · World J Urol · 2026-10-06
A systematic review and meta-analysis of 31 studies found peritoneal flap-based reconstruction significantly reduced symptomatic lymphocele after radical prostatectomy with pelvic lymph node dissection (pooled RCT data RR 0.57), with a larger effect in a sensitivity analysis of comparative studies.
Why it matters: Supports a simple, low-cost intraoperative technique to reduce a common post-prostatectomy complication.
Testosterone breakthrough during ADT intensification linked to worse outcomes in LATITUDE, not ARASENS Retrospective · BJU Int · 2026-10-06
Post hoc landmark analyses of two phase 3 mHSPC trials found testosterone breakthrough above 35 ng/dL was associated with worse overall survival in LATITUDE (HR 1.49) but not significantly in ARASENS (HR 1.18 for OS, HR 0.86 for time to CRPC).
Why it matters: Raises the question of whether monitoring and correcting testosterone breakthrough during ADT intensification could improve outcomes, though trial-specific differences warrant caution.
PSMA-guided radiotherapy intensification shows modest FFS benefit at 5 years Phase 1-2 · Eur Urol · 2026-10-04
In a phase 2 randomized trial (n=253), PSMA-PET-guided radiotherapy intensification to all detected sites did not significantly improve failure-free survival versus standard radiotherapy (66% vs 62% at 5 years), though freedom from biochemical progression favored the PSMA-guided arm.
Why it matters: Suggests PSMA-guided RT intensification may improve biochemical control but has not yet shown definitive failure-free survival benefit.
FDA approves denosumab biosimilar Degevma (Xgeva biosimilar) FDA approval · Renal & Urology News · 2026-10-03
The FDA approved Teva's denosumab biosimilar Degevma, referencing Xgeva, expanding options for skeletal-related event prevention in advanced genitourinary cancers with bone metastases.
Why it matters: Biosimilar approval may affect cost and access for bone-targeted therapy in men with bone-metastatic prostate cancer.
SOAR phase 2 trial: PSMA-directed salvage therapy without ADT feasible in oligorecurrent prostate cancer Phase 1-2 · UroToday · 2026-10-02
The SOAR phase 2 trial evaluated PET-defined metastasis-directed therapy without androgen deprivation in men with oligorecurrent prostate cancer, reporting on feasibility and outcomes of this ADT-sparing approach.
Why it matters: Adds phase 2 data on an ADT-sparing approach for selected oligorecurrent patients; randomized confirmation is still needed.
Updated Cochrane review: PSA screening modestly cuts prostate cancer deaths, overall mortality benefit uncertain Meta-analysis · BJU Int · 2026-10-02
An update of the Cochrane review pooling six randomized trials (789,086 participants) found PSA-based screening likely reduces prostate cancer-specific mortality (moderate-certainty evidence) but any effect on overall mortality remains uncertain, with low-certainty evidence of a small or null effect.
Why it matters: Provides the most current synthesis of screening trial evidence to inform shared decision-making conversations about PSA testing.

Bladder cancer news

Urinary ctDNA assay studied for detecting minimal residual disease in high-risk NMIBC Prospective · UroToday · 2026-10-05
A study evaluates whether a urinary circulating tumor DNA assay can detect minimal residual disease in patients with high-risk non-muscle invasive bladder cancer. Design details such as prospective or retrospective enrollment are not specified in the available source.
Why it matters: Non-invasive molecular monitoring could eventually complement cystoscopy for surveillance in high-risk NMIBC, pending further validation of study design and results.
Urine cell-free RNA test detects bladder cancer and predicts BCG response Prospective · Nat Med · 2026-10-04
A new urine cfRNA sequencing method (uRARE-seq) showed 95% sensitivity at 90% specificity for localized bladder cancer detection across 683 samples, outperformed urine tumor DNA analysis, and distinguished BCG responders from non-responders with an AUC of 0.93.
Why it matters: Could offer a noninvasive tool to detect recurrence and predict BCG response, pending prospective validation.
AUA releases guideline amendment for NMIBC management Guideline · OncLive · 2026-10-03
The American Urological Association issued an amendment to its non-muscle invasive bladder cancer guideline.
Why it matters: Guideline updates directly affect NMIBC management protocols in practice.
FDA grants priority review to durvalumab plus enfortumab vedotin for MIBC FDA action · Renal & Urology News · 2026-10-02
The FDA has granted priority review to a combination regimen of durvalumab and enfortumab vedotin for muscle-invasive bladder cancer, a regulatory step already reported for the same combination in the metastatic setting.
Why it matters: If approved for MIBC, this would extend the regimen into earlier-stage perioperative treatment.
Global survey: most high-risk NMIBC patients offered cystectomy refuse surgery Retrospective · BJU Int · 2026-10-03
In a multinational survey of 359 physicians on 2,583 patients with high-risk NMIBC, radical cystectomy was offered to 20% of BCG-treated patients but 68% refused, mainly citing quality of life, stoma aversion, and surgical safety concerns.
Why it matters: Highlights a real-world gap between guideline-recommended cystectomy and patient acceptance, reinforcing demand for effective bladder-sparing options.
Event-free and progression-free survival fall short as OS surrogates in BCG-naive HR-NMIBC Retrospective · World J Urol · 2026-10-03
An 18-center study of 3,384 patients with BCG-naive high-risk NMIBC found adequate BCG exposure improved overall survival, but pseudo-trial-level surrogacy for OS was moderate (R2 0.60 for PFS, 0.51 for EFS), below the prespecified adequacy threshold.
Why it matters: Raises caution about relying on EFS or PFS as primary endpoints in NMIBC immunotherapy trials without OS confirmation.
SAKK 06/19: adding intravesical BCG to perioperative chemoimmunotherapy in MIBC Phase 1-2 · MedPage Today · 2026-10-01
Primary analysis of the single-arm, open-label phase II SAKK 06/19 trial, which added intravesical recombinant BCG to perioperative chemoimmunotherapy in high-risk muscle-invasive bladder cancer.
Why it matters: An early-phase signal only: without a randomized control arm, the trial cannot show how much intravesical BCG adds.
Phase 1 trial: gemcitabine plus BCG retreatment shows high early response in BCG-exposed NMIBC Phase 1-2 · J Urol · 2026-10-02
In a 25-patient dose-escalation trial, alternating intravesical gemcitabine and BCG in BCG-exposed high-grade NMIBC was well tolerated with no dose-limiting toxicities, and 96% achieved complete clinical response at 6 months; a phase 3 trial comparing this combination to BCG alone is now underway.
Why it matters: Signals a potential strategy to improve BCG retreatment efficacy, pending confirmatory phase 3 data.
FDA proposes reclassifying blue light cystoscopy systems from Class III to Class II FDA action · UroToday · 2026-10-01
The FDA has proposed reclassifying blue light cystoscopy systems used for bladder cancer detection from Class III to Class II devices, a regulatory change welcomed by the manufacturer.
Why it matters: Reclassification could ease future device approvals and potentially expand access to blue light cystoscopy for NMIBC detection.
NCCN Bladder Cancer guidelines list gemcitabine intravesical system for BCG-unresponsive papillary-only NMIBC Guideline · NCCN · 2026-10-01
The NCCN Bladder Cancer guidelines (current Version 3.2026) list the gemcitabine intravesical system (Inlexzo) as a category 2A option for BCG-unresponsive high-risk NMIBC with Ta/T1 papillary-only disease without CIS, in addition to its listing for CIS with or without papillary tumors.
Why it matters: Extends a bladder-sparing option to the papillary-only BCG-unresponsive population, which joins the other agents listed for this setting; payer coverage commonly follows NCCN listing.

Kidney cancer news

Older age, unmarried status, and non-White race linked to lower use of adjuvant therapy after nephrectomy Retrospective · Urol Oncol · 2026-10-02
Among 6,497 SEER-identified patients eligible for adjuvant systemic therapy after nephrectomy for renal cell carcinoma, only 17.9% received it, with significantly lower uptake among those age 65 or older, unmarried, or non-Caucasian, and these factors compounded when combined.
Why it matters: Highlights disparities in guideline-concordant adjuvant therapy uptake that may warrant targeted outreach efforts.

Upper tract urothelial carcinoma news

CT urography and cytology miss most recurrences during UTUC endoscopic surveillance Retrospective · BJU Int · 2026-09-30
In a two-center study of 133 patients undergoing kidney-sparing endoscopic treatment for UTUC, combined CT urography and cytology avoided about 69% of surveillance ureteroscopies but missed nearly 65% of recurrences, with cytology alone highly specific but poorly sensitive.
Why it matters: Suggests noninvasive imaging and cytology cannot safely replace ureteroscopy for UTUC surveillance despite reducing procedure burden.
Meta-analysis: ureteroscopic biopsy forceps yield ~85% diagnostic rate in UTUC, no device superior Meta-analysis · J Endourol · 2026-09-29
Pooling 19 studies and over 1,700 biopsies, flexible ureteroscopy forceps achieved 84.6% diagnostic yield and 78.8% grade concordance in upper tract urothelial carcinoma, with over half of apparently non-muscle-invasive tumors upstaged at nephroureterectomy, and no forceps design outperforming others.
Why it matters: Reinforces that ureteroscopic biopsy alone should not be relied upon to exclude muscle-invasive UTUC when planning kidney-sparing therapy.

Testicular cancer news

EAU panel recommends centralized care to improve testicular cancer outcomes Guideline · UroToday · 2026-09-25
A European Association of Urology guidelines panel report argues that treatment at higher-volume centers is associated with better outcomes for testicular cancer patients, supporting centralization of care.
Why it matters: Referral pathways and case volume may influence outcomes in a highly curable cancer where errors have long-term consequences.

Endourology and stone disease news

Editorial weighs in on low- and ultra-low-dose CT for kidney stones in obesity Prospective · Urology · 2026-10-07
This is an editorial comment accompanying a multicenter review titled "Accuracy of Low-Dose and Ultra-Low-Dose CT for Nephrolithiasis in Obesity." The source provided is the editorial itself and does not include the underlying study's methods or results.
Why it matters: Urologists should note this is commentary on a separate multicenter review; no specific accuracy data are given in this source.
Contrast-enhanced ultrasound guidance beats fluoroscopy for PCNL renal access RCT · Eur Urol Focus · 2026-10-02
In a 150-patient randomized trial, dual contrast-enhanced ultrasound guidance achieved higher first-attempt puncture success, faster tract establishment, shorter hospital stay, and less blood loss than fluoroscopy during PCNL, with similar complication rates.
Why it matters: Offers a radiation-free alternative for renal access during PCNL with potentially better efficiency and safety.

Female pelvic medicine and neurourology news

AMA creates Category I CPT codes for implantable tibial neuromodulation in urge incontinence Policy · Urology Times · 2026-10-02
The AMA has issued dedicated Category I CPT codes for implantable tibial neuromodulation devices used to treat urgency urinary incontinence, moving the procedure out of unlisted-code billing.
Why it matters: New Category I codes typically improve payer recognition and reimbursement consistency for this neuromodulation option.
Lead migration after sacral neuromodulation more common with one device brand in single-center study Retrospective · Neurourol Urodyn · 2026-10-01
Among 445 patients undergoing sacral neuromodulation, 7.9% had confirmed lead migration; Axonics devices were associated with higher odds of migration than Medtronic devices, and all cases of large migration occurred with Axonics leads.
Why it matters: Device-specific migration risk may inform counseling and postoperative monitoring protocols for SNM patients.

Reconstruction and trauma news

Institutional experience improves 5-year outcomes for gender-affirming penile prosthesis Retrospective · J Sex Med · 2026-09-28
In a retrospective cohort of 473 patients undergoing first-time gender-affirming inflatable penile prosthesis insertion, cumulative institutional experience, single-cylinder implantation, and use of one device brand were linked to lower risk of subsequent surgery, with peak proficiency identified around case 311.
Why it matters: Highlights a long learning curve for gender-affirming IPP surgery, relevant for centers building or scaling these programs.
Novel laparoscopic technique described for refractory piriformis-related pelvic pain Retrospective · J Endourol · 2026-09-26
A retrospective series of 200 patients across multiple institutions describes a transgluteal laparoscopic piriformis muscle transection technique for chronic pelviperineal pain syndrome, reporting technical feasibility with low morbidity and short hospital stay.
Why it matters: Introduces a minimally invasive surgical option for a difficult-to-treat and underrecognized cause of chronic pelvic pain.
Advances in artificial urinary sphincter technology Interview · Urology Times · 2026-09-14
Andrew Peterson, MD, on electronic sphincter innovations for post-treatment incontinence.
Why it matters: Relevant to survivorship care after prostatectomy and radiation.

Pediatric urology news

Temporary vesicostomy cuts early complications after pediatric bladder augmentation Retrospective · Neurourol Urodyn · 2026-10-01
In 168 children undergoing ileocystoplasty with catheterizable stoma, temporary incontinent vesicostomy was associated with markedly lower rates of anastomotic leakage, stoma obstruction, and febrile UTI (2.3% vs 28.6% overall complication rate), without affecting 24-month continence or bladder dynamics.
Why it matters: Offers a technical strategy to reduce early morbidity and emergency readmissions after a common pediatric reconstructive procedure.
Review proposes risk-stratified framework for observation versus treatment of pediatric varicocele Review · Nat Rev Urol · 2026-10-01
This narrative review synthesizes evidence on pediatric varicocele management, noting lack of consensus, and proposes a risk-stratified model using grade, testicular volume asymmetry, and semen/hormonal parameters to guide observation versus early intervention.
Why it matters: Offers a practical framework for a common but controversial pediatric urology decision where high-quality outcome data are limited.
New reference curves define expected residual hydronephrosis after pyeloplasty Retrospective · World J Urol · 2026-09-27
In 566 renal units after pyeloplasty, postoperative APD reference curves were built from units without recurrence. Renal pelvic APD above the 90th centile curve was linked to a much higher reoperation rate (11.7% vs 0.8%).
Why it matters: Offers an objective benchmark to decide which children with residual postoperative dilation need closer follow-up versus reassurance.
Insurance status and timing linked to orchiectomy odds after testicular torsion in NY state Retrospective · J Pediatr Urol · 2026-09-27
Among 4,159 children with testicular torsion in New York State over 15 years, 26% underwent orchiectomy; government or self-pay insurance and presentation timing were associated with higher orchiectomy odds, with effects varying by age group.
Why it matters: Points to potential access or systems-level disparities affecting testicle salvage rates that may warrant institutional review.

Infection, transplant and general urology news

Global Burden of Disease 2023: urologic cancer incidence rising, death rates falling Retrospective · BJU Int · 2026-10-05
Analysis of GBD 2023 data shows prostate, bladder, kidney and testicular cancers caused 2.47 million incident cases and 0.88 million deaths in 2023, with rising incidence for testicular and kidney cancer but declining death rates across all four cancers since 1990.
Why it matters: Provides a global epidemiologic benchmark showing population growth and aging, not rising risk, drive most of the increase in case counts.

Practice and policy news

Southland NZ urology service faces collapse as surgeries continue to be cancelled News · 1News · 2026-10-01
Local reporting describes ongoing fears that Southland's urology service could collapse amid continued surgery cancellations, a story previously covered on this site.
Why it matters: Illustrates ongoing workforce and capacity strain affecting urology service delivery internationally.

More urology news

Trial opens testing PSMA bispecific antibody plus cancer vaccine in biochemically recurrent prostate cancer Trial opening · ClinicalTrials.gov · 2026-10-06
A phase 2 randomized trial will test a PSMAxCD3 bispecific antibody and a prostate cancer peptide vaccine, alone or combined, in patients with biochemical recurrence after local curative therapy.
Why it matters: Represents an emerging immunotherapy approach being explored in the biochemical recurrence setting.
ECOG-ACRIN opens trial of bipolar androgen therapy sequencing in mCRPC Trial opening · ClinicalTrials.gov · 2026-10-01
A phase II/III trial will compare high-dose testosterone (bipolar androgen therapy) followed by darolutamide against usual care in 432 patients with metastatic castration-resistant prostate cancer.
Why it matters: Bipolar androgen therapy is an active area of investigation for resensitizing castration-resistant tumors to androgen pathway agents.
Phase 3 trial opens testing [177Lu]Ludotadipep in metastatic CRPC Trial opening · ClinicalTrials.gov · 2026-10-01
A new phase 3 trial sponsored by FutureChem will randomize 114 patients with metastatic castration-resistant prostate cancer to a radioligand therapy, with radiographic progression-free survival as the primary endpoint.
Why it matters: Represents continued expansion of PSMA-targeted radioligand therapy options in mCRPC beyond currently approved agents.
Phase 1-2 trial opens testing REGN21353 alone or with nezastomig in mCRPC Trial opening · ClinicalTrials.gov · 2026-09-30
A new phase 1-2 study will evaluate experimental agent REGN21353, alone or combined with nezastomig (and sarilumab in some participants), in previously treated metastatic castration-resistant prostate cancer. Planned enrollment is 192 patients.
Why it matters: Adds another bispecific/immunotherapy combination trial for heavily pretreated mCRPC patients who may be candidates for trial referral.

Loading today's edition…